

**COVID-19 infection and recovery**  
**amongst patients with moderate-to-severe lupus during the pandemic**  
Results from the BILAG-biologics register


Sarah Dyball, Mia Rodziewicz, Emily Sutton, Ben Parker, Ian N Bruce on behalf of the BILAG-BR

**COVID-19 infection**

**Demographics of 202 lupus patients completing COVID19 questionnaire**

Age/ years, median (IQR)	51 (38-61)
Female, n (%)	186 (92.1)
Ethnicity	
White, n(%)	150 (74.3)
Black, n(%)	10 (5.0)
Asian, n(%)	24 (11.9)
Time on register/ years, median (IQR)	4 (2-7)
Currently smoke, n (%)	58 (28.7)
Rituximab ever, n(%)	165 (81.7)
Belimumab ever, n(%)	33 (16.3)
Cyclophosphamide ever, n(%)	54 (26.7)
Parental steroids last year, n(%)	60 (29.7)
Oral steroids last year, n(%)	138 (68.3)
Current pred/ mg, median (IQR)	5 (5-8)

**Full recovery in only a third of patients**



This raises concerns over the potential risk of long COVID in patients with lupus

**BILAG-BR:**  
Prospective biologics registry  
2010-2022  
**1387 patients**

UK Office for National statistics  
  
Dec 2019-Jan 2022  
  
4 patients died from COVID-19

**COVID19 Questionnaire**  
First **202/1268** patients to respond  
From 37 centres

Responses linked with BILAG-BR  
  
9<sup>th</sup> Oct 2021-7<sup>th</sup> Jan 2022  
  
Paper or online questionnaire

**COVID19 infection**  
20/202 positive tests

Patients receiving:  
5 belimumab  
4 RTX  
1 tocilizumab  
2 cyclo-phosphamide

3 hospitalised  
1 required ICU

2 Unvaccinated  
1 RTX + cyclo-phosphamide